论文部分内容阅读
AIM To describe racial/ethnic differences in treatment and survival among liver cancer patients in a populationbased cancer registry.METHODS Invasive cases of primary hepatocellular carcinoma, n = 33270, diagnosed between January 1, 1988-December 31, 2012 and reported to the California Cancer Registry were analyzed by race/ethnicity, age, gender, geographical region, socio-economic status, time period of diagnosis, stage, surgical treatment, and survival. Patients were classified into 15 racial/ethnic groups: non-Hispanic White(White, n = 12710), Hispanic(n = 8500), Chinese(n = 2723), non-Hispanic Black(Black, n = 2609), Vietnamese(n = 2063), Filipino(n = 1479), Korean(n = 1099), Japanese(n = 658), American Indian/Alaskan Native(AIAN, n = 281), Laotian/Hmong (n = 244), Cambodian(n = 233), South Asian(n = 190), Hawai`ian/Pacific Islander(n = 172), Thai(n = 95), and Other Asian(n = 214). The main outcome measures were receipt of surgical treatment, and cause-specific and all-cause mortality.RESULTS After adjustment for socio-demographic characteristics, time period, and stage of disease, compared to Whites, Laotian/Hmong [odds ratio(OR) = 0.30, 95%CI: 0.17-0.53], Cambodian(OR = 0.65, 95%CI: 0.45-0.96), AIAN(OR = 0.66, 95%CI: 0.46-0.93), Black(OR = 0.76, 95%CI: 0.67-0.86), and Hispanic(OR = 0.78, 95%CI: 0.72-0.84) patients were less likely, whereas Chinese(OR = 1.58, 95%CI: 1.42-1.77), Koreans(OR = 1.45, 95%CI: 1.24-1.70), Japanese(OR = 1.41, 95%CI: 1.15-1.72), and Vietnamese(OR = 1.26, 95%CI: 1.12-1.42) were more likely to receive surgical treatment. After adjustment for the same covariates and treatment, cause-specific mortality was higher for Laotian/Hmong [(hazard ratio(HR) = 1.50, 95%CI: 1.29-1.73)], Cambodians(HR = 1.35, 95%CI: 1.16-1.58), and Blacks(HR = 1.07, 95%CI: 1.01-1.13), and lower for Chinese(HR = 0.82, 95%CI: 0.77-0.86), Filipinos(HR = 0.84, 95%CI: 0.78-0.90), Vietnamese(HR = 0.85, 95%CI: 0.80-0.90), Koreans(HR = 0.90, 95%CI: 0.83-0.97), and Hispanics(HR = 0.91, 95%CI: 0.88-0.94); results were similar for all-cause mortality.CONCLUSION Disaggregated data revealed substantial racial/ethnic differences in liver cancer treatment and survival, demonstrating the need for development of targeted interventions to mitigate disparities.
AIM To describe racial / ethnic differences in treatment and survival among liver cancer patients in a population based cancer registry. METHODS Invasive cases of primary hepatocellular carcinoma, n = 33270, diagnosed between January 1, 1988-December 31, 2012 and reported to the California Cancer Patients were analyzed by race / ethnicity, age, gender, geographical region, socio-economic status, time period of diagnosis, stage, surgical treatment, and survival. Patients were classified into 15 racial / ethnic groups: non-Hispanic White (White, Hispanic (n = 8500), Chinese (n = 2723), non-Hispanic Black (n = 2609), Vietnamese (n = 2063), Filipino (n = 1479), Korean , American Indian / Alaskan Native (AIAN, n = 281), Laotian / Hmong (n = 244), Cambodian (n = 233), South Asian (n = 190), Hawaiian / Pacific Islander (n = 172), Thai (n = 95), and Other Asian (n = 214). The main outcome measures were receipt of surgical treatment, and cause-specific and all-cause mortal ity.RESULTS After adjustment for socio-demographic characteristics, time period, and stage of disease, compared to Whites, Laotian / Hmong odds ratio (OR) = 0.30, 95% CI: 0.17-0.53, Cambodian (OR = (OR = 0.66, 95% CI: 0.46-0.93), Black (OR = 0.76, 95% CI: 0.67-0.86), and Hispanic (OR = 0.78, 95% CI: Kore (OR = 1.45, 95% CI: 1.24-1.70), Japanese (OR = 1.41, 95% CI: 1.42-1.77) 1.15-1.72), and Vietnamese (OR = 1.26, 95% CI: 1.12-1.42) were more likely to receive surgical treatment. After adjustment for the same covariates and treatment, cause-specific mortality was higher for Laotian / Hmong [(hazard (HR = 1.35, 95% CI: 1.16-1.58), and Blacks (HR = 1.07, 95% CI: 1.01-1.13), and lower Vietnamese (HR = 0.85, 95% CI: 0.77-0.86), Filipinos (HR = 0.84, 95% CI: 0.78-0.90), Vietnamese 0.90, 95% CI: 0.83-0.97), and Hispanics (HR = 0.91, 95% CI: 0.88-0.94); results were similar for all-cause mortality. CONCLUSION Disaggregated data showed substantial racial / ethnic differences in liver cancer treatment and survival, demonstrating the need for development of targeted interventions to mitigate disparities.